Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Biotechs Promote “Relationship Building” In Developing Marketing Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Eisai and Astellas execs tell BIO attendees that forming strong initial partnerships provides a basis for expanding alliances into new products and geographies.

You may also be interested in...

Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition

Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.

Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.

Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head

But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts